Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
Dept of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, member of the German Center for Lung Research (DZL), Munich, Germany Katrin.Milger@med.uni-muenchen.de.
Katrin
K
Milger
Dept of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, member of the German Center for Lung Research (DZL), Munich, Germany.
Nikolaus
N
Kneidinger
Dept of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, member of the German Center for Lung Research (DZL), Munich, Germany.
Claus
C
Neurohr
Dept of Respiratory Medicine, Asklepios Clinic Gauting, Comprehensive Pneumology Center, member of the German Center for Lung Research (DZL), Munich, Germany.
Frank
F
Reichenberger
Dept of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, member of the German Center for Lung Research (DZL), Munich, Germany Dept of Respiratory Medicine, Asklepios Clinic Gauting, Comprehensive Pneumology Center, member of the German Center for Lung Research (DZL), Munich, Germany.
Jürgen
J
Behr
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015992:Body Mass Index; D057176:Compassionate Use Trials; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011728:Pyridones / Q000009:adverse effects* / Q000627:therapeutic use; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D014797:Vital Capacity
D000893:Anti-Inflammatory Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D011728:Pyridones; C093844:pirfenidone; C530716:nintedanib